GET THE APP

Gankyrin: A novel gene that promotes tamoxifen resistance in breast cancer patients
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Gankyrin: A novel gene that promotes tamoxifen resistance in breast cancer patients


14th World Cancer & Anti-Cancer Therapy Convention

November 21-23, 2016 Dubai, UAE

Khadijeh Jamialahmadi, Rosa Jahangiri, Masoumeh Gharib and Amirnader Emami Razavi

Mashhad University of Medical Sciences, Iran
Tehran University of Medical Sciences, Iran

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Breast cancer is the most frequent malignancy in women worldwide. Oestrogen receptor ?± (ER?±) antagonists like tamoxifen are used in endocrine therapies for ER?±-positive (ER?±+) breast cancer patients. Unfortunately, the clinical benefit is limited due to intrinsic and acquired drug resistance. Gankyrin (P28GANK) is a newly defined oncoprotein which was reported to confer a multidrug resistant phenotype in some cancer cells. Gankyrin also functions as a dual-negative regulator of the two most important tumor suppressor pathways: (I) INK4-CDK-pRb, and (II) ARF-MDM2-p53. In the present study, the levels of protein expression and mRNA transcripts were determined using immunohistochemical analysis and Real-Time quantitative PCR in 72 matched formalinfixed paraffin-embedded and fresh frozen breast cancer tissues (36 tamoxifen resistant and 36 tamoxifen sensitive). Overexpression of P28GANK was present in about 56% of the tamoxifen sensitive breast cancer patients and more frequently (91%) in tamoxifenrefractory tumors. P28GANK gene was also found to be overexpressed at the protein level in tamoxifen resistance patients compared to tamoxifen sensitive samples (p=0.045). These results for the first time suggest that Gankyrin plays a role in tamoxifen-resistant breast cancer, and the inhibition of this oncoprotein may be a potential target for re-sensitizing the resistant breast cancer patients to tamoxifen-treatment in endocrine-resistant breast cancer patients

Biography :

Khadijeh Jamialahmadi has completed her PhD from Tehran University of Medical Sciences, School of Pharmacy, Tehran, Iran. She is an Assistant Professor in the Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran. She has published more than 30 papers in reputed journals. Her current research interests are cancer targeted therapy, cancer epigenetics, identification of new biomarkers and therapeutic targets in cancer and multi drug resistance in cancer.

Email: jamialahmadikh@mums.ac.ir

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward